Laboratory Diagnosis of SARS-CoV-2 Pneumonia.
Melissa R. Gitman,Maryia V. Shaban,Alberto Paniz-Mondolfi,Emilia Mia Sordillo +3 more
- Vol. 11, Iss: 7, pp 1270
TLDR
In this paper, the authors delineate the categories of testing measures developed to date, analyze the efficacy of collecting patient specimens from diverse regions of the respiratory tract, and present the up and coming technologies which have made pathogen identification easier and more accessible to the public.Abstract:
The emergence and rapid proliferation of Coronavirus Disease-2019, throughout the past year, has put an unprecedented strain on the global schema of health infrastructure and health economy. The time-sensitive agenda of identifying the virus in humans and delivering a vaccine to the public constituted an effort to flatten the statistical curve of viral spread as it grew exponentially. At the forefront of this effort was an exigency of developing rapid and accurate diagnostic strategies. These have emerged in various forms over the past year-each with strengths and weaknesses. To date, they fall into three categories: (1) those isolating and replicating viral RNA in patient samples from the respiratory tract (Nucleic Acid Amplification Tests; NAATs), (2) those detecting the presence of viral proteins (Rapid Antigen Tests; RATs) and serology-based exams identifying antibodies to the virus in whole blood and serum. The latter vary in their detection of immunoglobulins of known prevalence in early-stage and late-stage infection. With this review, we delineate the categories of testing measures developed to date, analyze the efficacy of collecting patient specimens from diverse regions of the respiratory tract, and present the up and coming technologies which have made pathogen identification easier and more accessible to the public.read more
Citations
More filters
Journal ArticleDOI
Probing the mutation independent interaction of DNA probes with SARS-CoV-2 variants through a combination of surface-enhanced Raman scattering and machine learning
TL;DR: In this article , a set of DNA probes targeting a specific segment of the nucleocapsid phosphoprotein (N) gene of SARS-CoV-2 with high binding efficiency was developed.
Journal ArticleDOI
A Novel Rapid Test to Detect Anti-SARS-CoV-2 N Protein IgG Based on Shear Horizontal Surface Acoustic Wave (SH-SAW)
Yu-Chi Peng,Chia-Hsuan Cheng,Hiromi Yatsuda,Szu-Heng Liu,Shih-Jen Liu,Takashi Kogai,Chen-Yen Kuo,Robert Wang +7 more
TL;DR: In this article, a shear-horizontal surface acoustic wave (SH-SAW) biosensor was developed to detect the anti-SARS-CoV-2 nucleocapsid antibody.
Journal ArticleDOI
Laboratory Diagnosis for SARS-CoV-2 Infection
TL;DR: The optimal diagnostic test for SARS-CoV-2 infection should be selected based on a patient's clinical syndrome and presentation in relation to symptom onset as mentioned in this paper , and the optimal test should be chosen based on the patient's symptoms and presentation.
Journal ArticleDOI
Comparative analysis of chest radiography and lung ultrasound to predict intra-hospital prognosis of patients admitted for acute SARS-CoV-2 pneumonia (COVID-19)
Jorge Rubio-Gracia,David Ibañez-Muñoz,Ignacio Giménez-López,Vanesa Garcés-Horna,Daniel López-Delgado,Jose Luis Sierra-Monzón,Silvia Crespo-Aznárez,Natacha Peña-Fresneda,Juan Ignacio Pérez-Calvo,Marta Sánchez-Marteles +9 more
TL;DR: In this paper , a comparison between the Schalekamp radiological lung scale and LUZ-score ultrasound scale was performed in stable COVID-19 patients, and the results showed that the LUZ scale failed to identify patients at higher risk at admission for the primary end-point.
Journal ArticleDOI
Peptide Binder with High-Affinity for the SARS-CoV-2 Spike Receptor-Binding Domain
TL;DR: The R1 peptide exhibited high-affinity for specific binding with the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein with a dissociation constant KD of (7.5 ± 1.9) × 10–10 M, which maintained high binding affinity with the RBD derived from Gamma, Lambda, Delta, and Omicron variants.
References
More filters
Journal ArticleDOI
Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use Authorization Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Individuals Diagnosed with COVID-19.
Daniel D. Rhoads,Daniel D. Rhoads,Sree S. Cherian,Sree S. Cherian,Katharine P. Roman,Lisa M. Stempak,Lisa M. Stempak,Christine L. Schmotzer,Christine L. Schmotzer,Navid Sadri,Navid Sadri +10 more
TL;DR: Dozens of in vitro diagnostics have received emergency use authorization (EUA) from the U.S. Food & Drug Administration for the detection of SARS-CoV-2, but little has been studied to determine how well these assays perform using clinical specimens.
Journal ArticleDOI
A Recurrent Mutation at Position 26340 of SARS-CoV-2 Is Associated with Failure of the E Gene Quantitative Reverse Transcription-PCR Utilized in a Commercial Dual-Target Diagnostic Assay.
Maria Artesi,Sébastien Bontems,Paul Gobbels,Marc Franckh,Piet Maes,Raphaël Boreux,Cécile Meex,Pierrette Melin,Marie-Pierre Hayette,Vincent Bours,Keith Durkin +10 more
TL;DR: The identification of a C-to-U transition at position 26340 of the SARS-CoV-2 genome that is associated with failure of the cobas Sars-Cov-2 E gene qRT-PCR in eight patients is reported, highlighting the necessity of monitoring SARS, CoV- 2 for the emergence of single-nucleotide polymorphisms that might adversely affect RT-PCRs used in diagnostics.
Journal ArticleDOI
Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test.
Michael J. Loeffelholz,David Alland,Susan M. Butler-Wu,Utsav Pandey,Carlo Frederico Perno,Alice Nava,Karen C. Carroll,Heba H. Mostafa,Emma Davies,Ashley McEwan,Jennifer L. Rakeman,Randal C. Fowler,Jean-Michel Pawlotsky,Slim Fourati,Sukalyani Banik,Padmapriya P. Banada,Shobha Swaminathan,Soumitesh Chakravorty,Robert Kwiatkowski,VC Chu,Jo Ann Kop,Rajiv L. Gaur,Mandy L. Y. Sin,Duy Nguyen,Simranjit Singh,Na Zhang,David H. Persing +26 more
TL;DR: The Xpert test provided sensitive and accurate detection of SARS-CoV-2 in a variety of upper- and lower-respiratory-tract specimens and the high sensitivity and short time to results of approximately 45 min may impact patient management.
Journal ArticleDOI
The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing.
Kimberly E. Hanson,Angela M. Caliendo,Cesar A. Arias,Mary K. Hayden,Janet A. Englund,Mark J Lee,Mark Loeb,Robin Patel,Abdallah El Alayli,Osama Altayar,Payal M. Patel,Yngve Falck-Ytter,Valery Lavergne,Rebecca L. Morgan,M. Hassan Murad,Shahnaz Sultan,Adarsh Bhimraj,Reem A. Mustafa +17 more
TL;DR: The IDSA panel weighed available diagnostic evidence and recommends nucleic acid testing for all symptomatic individuals suspected of having COVID-19, and testing is recommended for asymptomatic individuals with known or suspected contact with a CO VID-19 case.
Journal ArticleDOI
Molecular and Immunological Diagnostic Tests of COVID-19: Current Status and Challenges.
TL;DR: This review focuses on a broad description of currently available diagnostic tests to detect either the virus (SARS-CoV-2) or virus-induced immune responses and lays out the shortcomings of certain tests and future needs.